Charles Dolladille

2.9k total citations · 1 hit paper
57 papers, 1.5k citations indexed

About

Charles Dolladille is a scholar working on Oncology, Toxicology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Charles Dolladille has authored 57 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Toxicology and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Charles Dolladille's work include Pharmacovigilance and Adverse Drug Reactions (13 papers), Drug-Induced Adverse Reactions (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Charles Dolladille is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (13 papers), Drug-Induced Adverse Reactions (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Charles Dolladille collaborates with scholars based in France, United States and Italy. Charles Dolladille's co-authors include Joachim Alexandre, Stéphane Éderhy, Basile Chrétien, Marion Sassier, Franck Thuny, Jennifer Cautela, Anne‐Flore Plane, Damien Legallois, Angélique Da Silva and Sophie Fédrizzi and has published in prestigious journals such as Nature Communications, Blood and Circulation Research.

In The Last Decade

Charles Dolladille

53 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

2020 377 citations Charles Dolladille, Stéphane Éderhy et al. profile →

Peers

Countries citing papers authored by Charles Dolladille

Since Specialization

Citations

This map shows the geographic impact of Charles Dolladille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Dolladille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Dolladille more than expected).

Fields of papers citing papers by Charles Dolladille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Dolladille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Dolladille. The network helps show where Charles Dolladille may publish in the future.

Co-authorship network of co-authors of Charles Dolladille

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Dolladille. A scholar is included among the top collaborators of Charles Dolladille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Dolladille. Charles Dolladille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between antidepressant drugs and falls in older adults: A mediation analysis in the World Health Organization's pharmacovigilance database 2025 ·Therapies ·(unknown), (unknown), Basile Chrétien, (unknown), (unknown), (unknown), Clémence Bechade, Thierry Lobbedez, Véronique Lelong‐Boulouard, Charles Dolladille	0
2	Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study 2025 ·Journal of Neurology ·(unknown), (unknown), Basile Chrétien, (unknown), Joachim Alexandre, Charles Dolladille, Angélique Da Silva	0
3	Identification of Anticancer Drugs Associated With Cancer Therapy‐Related Cardiac Dysfunction in Pediatrics—Analysis of the WHO Pharmacovigilance Database 2025 ·Pediatric Blood & Cancer ·Fabien Labombarda, Jérémie Rouger, Damien Legallois, Charles Dolladille, (unknown), Basile Chrétien	2
4	Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase 2024 ·BMJ Open ·(unknown), (unknown), Véronique Lelong‐Boulouard, Basile Chrétien, (unknown), Joachim Alexandre, Charles Dolladille, (unknown)	1
5	Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study 2024 ·Fundamental and Clinical Pharmacology ·(unknown), (unknown), (unknown), Charles Dolladille, Sophie Postel‐Vinay, Angélique Da Silva, Joachim Alexandre, Pierre‐Marie Morice	0
6	Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database 2024 ·Leukemia ·Joachim Alexandre, (unknown), (unknown), (unknown), Gandhi Damaj, Anne‐Flore Plane, Damien Legallois, Paul Milliez, Charles Dolladille, Basile Chrétien	2
7	Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization’s global pharmacovigilance database 2024 ·BMC Geriatrics ·(unknown), (unknown), (unknown), Basile Chrétien, (unknown), (unknown), Marion Sassier, Melissa St. Pierre, Olivier Martinaud, Charles Dolladille, Véronique Lelong‐Boulouard	4
8	State of the Art of Probiotic Use in Neonatal Intensive Care Units in French-Speaking European Countries 2023 ·Children ·(unknown), Charles Dolladille, Isabelle Goyer, Olivier Join‐Lambert, (unknown)	3
9	Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials 2023 ·JACC CardioOncology ·Joachim Alexandre, (unknown), Pierre‐Marie Morice, Marion Sassier, Angélique Da Silva, Anne‐Flore Plane, (unknown), Paul Milliez, Damien Legallois, Charles Dolladille	10
10	Infections associated with clozapine: a pharmacovigilance study using VigiBase® 2023 ·Frontiers in Pharmacology ·Basile Chrétien, Perrine Brazo, Angélique Da Silva, Marion Sassier, Charles Dolladille, Véronique Lelong‐Boulouard, Joachim Alexandre, Sophie Fédrizzi	5
11	Hypoxia Associated With Dihydropyridine Calcium Channel Inhibitors: A Pharmacovigilance Study in VigiBase 2023 ·Clinical Pharmacology & Therapeutics ·Basile Chrétien, (unknown), (unknown), Charles Dolladille, (unknown), Joachim Alexandre, (unknown)	2
12	Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database 2023 ·Frontiers in Pharmacology ·(unknown), Basile Chrétien, (unknown), Charles Dolladille, Angélique Da Silva, Ahmad Nehme, Florence Joly, Véronique Lelong‐Boulouard, (unknown)	6
13	Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review 2022 ·Frontiers in Medicine ·Mathieu Jozwiak, Guillaume Géri, Driss Laghlam, (unknown), Charles Dolladille, Lee S. Nguyen	10
14	Neonatal Hypotonia Following in Utero Exposure to Antidepressant Drugs 2022 ·The Journal of Pediatrics ·(unknown), Charles Dolladille, Basile Chrétien, (unknown), Sophie Fédrizzi, (unknown), Gisèle Apter, Joachim Alexandre, Fabian Guenolé	3
15	Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis 2021 ·Neurotherapeutics ·Charles Dolladille, Basile Chrétien, Laure Peyro‐Saint‐Paul, Joachim Alexandre, Olivier Dejardin, Sophie Fédrizzi, Gilles Defer	24
16	Management of Immune Checkpoint Inhibitor–Induced Myocarditis 2021 ·JACC CardioOncology ·Franck Thuny, Joachim Alexandre, Joe‐Elie Salem, Mariana Mirabel, Charles Dolladille, Alain Cohen‐Solal, Ariel Cohen, Stéphane Éderhy, Jennifer Cautela	24
17	Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase^® 2020 ·Psychological Medicine ·Basile Chrétien, Véronique Lelong‐Boulouard, Sylvain Chantepie, Marion Sassier, (unknown), Perrine Brazo, Xavier Humbert, Joachim Alexandre, Sophie Fédrizzi, Charles Dolladille	27
18	Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis 2020 ·Archives of cardiovascular diseases ·Charles Dolladille, (unknown), Théodora Bejan‐Angoulvant, Khalil Zaman, Marion Sassier, (unknown), Andreea Stefan, Anne‐Flore Plane, Damien Legallois, Paul Milliez, Jean‐Jacques Parienti, Joachim Alexandre	5
19	Clinically significant drug-drug interactions between tramadol and CYP3A4 inhibitors: disproportionality analysis in VigiBase® and hypothesis on the underlying mechanism 2020 ·European Journal of Clinical Pharmacology ·(unknown), Charles Dolladille, (unknown), Marion Sassier, (unknown), Véronique Lelong‐Boulouard, Joachim Alexandre, (unknown), Sophie Fédrizzi, Basile Chrétien	4
20	Fibrates et risques thrombo-emboliques veineux : étude cas/non-cas dans la base nationale de pharmacovigilance 2017 ·Therapies ·Xavier Humbert, Charles Dolladille, Marion Sassier, Marie‐Blanche Valnet‐Rabier, Thierry Vial, Emmanuelle Bondon‐Guitton, (unknown), (unknown), (unknown), Antoine Coquerel, Joachim Alexandre, Sophie Fédrizzi	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact